AddLife Year-end report February, 2017

AddLife introduction A leading independent player mainly in the Nordic Life Science market Markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector in the Nordics 30 subsidiaries Labtech and Medtech Net sales ~SEK 1 950m

Other markets/operations AddLife Markets Other markets/operations Production plant Key markets

Customer offering – built on 4 cornerstones Products from leading suppliers Qualified advisory services Strong local service and support Training services

”Radiometer award – 75 years of partnership!”

Two business areas Labtech Products Customers Companies Medtech

Decentralized organization with entrepreneurial business acumen Combine the small company’s… With the large company’s… Flexibility Resources ”Small scale business – large scale wise” Personality Network Effectiveness Sustainability

Year-end &Q3 2016

Highlights Q3 ”Record quarter concludes the year” Net Sales SEK 612m (472), +30%, organic, +21% EBITA SEK 76m (42), +80% Year-end, 9 months Net Sales SEK 1.486m (1,110), +34%, organic, +13% EBITA SEK 154m(100), +54% Proposes a dividend of SEK 1.50 per share for the shortened financial year

Market update Q3 & Year-end 2016 The market continues to develop positively and so do our companies. Our organic growth outperforms the market both in the Q3 and 2016! Positive development in all Nordic countries from the healthcare sector, especially within diagnostics, both instruments and consumables. High competition for large public tenders. Increased investments within start-up companies and innovation clusters. Acqusitions of Svan Care and Biolin Scientific in Q3, adding SEK 135m in annual sales Integration of Medline in Q3, adding SEK 40m in annual sales Acquired companies and integrated businesses during 2016, adding totally ~ SEK 275m in annual sales, developed well and according to plan Events after the period: Acquisition of Techno Medica, ~ SEK 30m in annual sales

Market update Q3 & Year-end 2016 Both public and private grants to different research-projects within Life Science. Somewhat lower investments in public research. Pharma industry continues to be strong. Digital marketing efforts yielding results. Somewhat weaker demands in university research, but increased sales of consumables. Continued stable market. Increased number of tenders from primary care. Continued increase growth outside the Nordics

Labtech Comments Organic sales growth of 26% in Q and 16% YTD Acquired sales growth of 6% in Q and 2% YTD Biolin Scientific acquired in Q3 The market continue to develop positively, especially for the diagnostics Both high instrument sales and high sales of consumables Severe influenza season Focused digital marketing and webshop in Denmark EBITA increase during Q3 by 65%, corresponding to an EBITA-margin of 15.6% (12.5) EBITA increase during YTD by 39%, corresponding to an EBITA-margin of 12.8% (10.9) YoY +33%

Medtech Comments Organic sales growth of 12% in Q and 7% YTD Acquired sales growth of 12% in Q and 62% YTD Svan Care acquired and Medline integrated in Q3 Demand from health services continues to develop favorably Growth is strongest in Sweden, Finland and Benelux Challenging market with strong competition Improved product mix to own products within ear, nose and throat together with infusion and surgery EBITA increased during Q3 by 63% corresponding to an EBITA- margin of 9.0% (6.9) EBITA increased during YTD by 120% corresponding to an EBITA-margin of 8.0% (6.2) YoY +24%

Profitability (P/WC) Cash Flow Cash flow from operating activities amounted to SEK 96m (62) Increased operating cash due to higher profit For the nine month period, other financing activities are the net of rights issue of SEK 300m, payment of bank loan of SEK 250m and repurchase of own shares SEK 33m Return on working capital (P/WC) amounted to 62% (64) Change in P/WC is attributable to the increase EBITA

Balance sheet Rights issue of SEK 300m in Q1 Repurchase of own shares SEK 33.1m

Selected key financial ratios

Q & A